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Little is known about the developmental functions of chromatin regulators that can deubiquitinate histones.
In this issue of Immunity, Jiang et al. (2011) demonstrate that the deubiquitinase MYSM1 is part of an epige-
netic switch that turns on B cell development.The B cell developmental pathway serves
as a powerful experimental model for
elucidating the network of transcription
factors that orchestrate cell fate specifi-
cation and commitment (Singh et al.,
2005). B-lymphocytes develop from
lymphoid-primed multipotent progenitors
(LMPPs) in the bone marrow that also
give rise to myeloid progeny such as
macrophages, dendritic cells, and granu-
locytes. Early B cell development is criti-
cally dependent on five transcriptional
regulators, PU.1, Ikaros, E2A, EBF1, and
Pax5. Of these, PU.1, Ikaros, and E2A
are expressed in LMPPs and are impor-
tant for the development of multiple
hematopoietic lineages, whereas EBF1
and Pax5 are sequentially expressed in
B-lymphoid progenitors and required
specifically for B cell development. EBF1
plays a particularly pivotal role within the
network of B lineage transcription factors
because its induction directs LMPPs
along the B cell pathway and restricts
alternate lineage options (Pongubala
et al., 2008). EBF1 functions synergisti-
cally with E2A to activate the transcription
of early B lineage genes that encode
components of the pre-B cell receptor
and the two factors also promote DNA
rearrangements at the immunoglobulin
heavy-chain (Igh) locus. EBF1 is required
for the induction of Pax5, which functions
in concert with EBF1 to establish and
maintain B cell fate commitment. Com-
paratively less is known about the inter-
play of these transcription factors with
chromatin modifications that are neces-
sary for the precise developmental control
of B lineage gene activity. Alterations in
chromatin structure are regulated by a
diverse set of histone modifying enzymes
aswell as by ATP-dependent nucleosome
remodeling complexes (Shilatifard, 2006).
In this issue of Immunity, Jiang et al.
(2011) uncover a novel molecular mecha-nism that appears to involve an E2A-
dependent alteration of chromatin struc-
ture at the Ebf1 gene resulting in its
developmental induction. Themechanism
involved recruitment of the MYSM1
histone H2A deubiquitinase, whose local-
ized action resulted in the conversion of
pre-existing repressive histone modifica-
tions at Ebf1 regulatory sequences into
their activating counterparts (Figure 1).
Accordingly, genetic ablation of the
Mysm1 gene resulted in a block to early
B cell development accompanied with
the failure to induce EBF1. This develop-
mental block could be rescued by resto-
ration of EBF1 expression.
A diverse set of covalent histone modi-
fications have been shown to regulate
chromatin structure and gene transcrip-
tion. These include acetylation, methyla-
tion, phosphorylation, SUMOylation, and
ubiquitination (Shilatifard, 2006). Of these,
monoubiquitination of histone H2B has
been associated with transcriptional acti-
vation, promoted by the onset of addi-
tional activating histone modifications,
such as methylation of lysine at position
4 of histone H3 (H3K4) and H3K79 (Lee
et al., 2010). On the other hand, monoubi-
quitination of histone H2A has been asso-
ciated with transcriptional silencing. In the
mammalian nucleus, H2A is the most
abundant ubiquitinated protein. Monoubi-
quitination of H2A has been linked to Pol-
ycomb group complex-dependent gene
silencing as well as X chromosome inacti-
vation (Clague et al., 2008). Furthermore,
the dynamic expression of many genes
appears to be dependent on a temporal
cycle of H2B ubiquitination and deubiqui-
tination (Henry et al., 2003). However, the
key biological and molecular functions of
the large class of deubuitinating enzymes
remain largely unexplored. Jiang et al.
(2011) have taken an important step in
illuminating this exciting area by under-Immunity 35, Dtaking a rigorous genetic and molecular
analysis of MYSM1 function in B cell
development.
The Myb-like, SWIRM, and MPN
domain-containing protein 1 (MYSM1) is
a histone H2A deubiquitinase and is
a component of a multiprotein complex
that includes the histone acetyltransfer-
ase PCAF (Zhu et al., 2007). Jiang et al.
(2011) demonstrate that genetic ablation
of theMysm1 gene resulted in a profound
and specific block at an early stage in B
cell development. This developmental
block was shown to be cell-intrinsic on
the basis of transplantation of Mysm1/
hematopoietic progenitors and the anal-
ysis of their progeny in chimeric animals.
The developmental block caused by the
loss of MYSM1 occurred at a similar stage
(pre-pro-B) that had been described
for the Ebf1/ mice, and importantly,
Mysm1/ common lymphoid progenitors
(CLPs) evidence a dramatic reduction of
the Ebf1 as well as Pax5 genes. In order
to determine whether the arrest in early
B cell development in MYSM1-deficient
lymphoid progenitors was due to low
amounts of EBF1, the authors restored
the expression of EBF1 in Mysm1/
hematopoietic progenitors. These cells
upon transduction with an EBF1-encod-
ing viral vector were able to form
B-lineage colonies that comprised
CD19+ B lineage precursors. The rescue
of B cell development was not observed
in Mysm1/ hematopoietic progenitors
transduced with Pax5, suggesting that
MYSM1 controls B cell development by
regulating the transcriptional activation
of the Ebf1 gene.
Next, the authors sought to uncover
the molecular mechanism by which
MYSM1 induces transcription of the
Ebf1 gene during B cell development.
Using chromatin crosslinking and immu-
noprecipitation (ChIP) assays, the authorsecember 23, 2011 ª2011 Elsevier Inc. 847
Figure 1. Model Depicting an Epigenetic Switch that Is Used to
Regulate the Activation of the Ebf1 Gene during B Cell Fate
Specification
The Ebf1 promoter and enhancer region exists in a repressed state as a conse-
quence of the action of Bmi1-containing complexes that result in histone H2A
monoubuitination and H3K27me3. The concerted action of the transcription
factor E2A along with the H2A deubiquitinase MYSM1 initiates local alteration
of chromatin structure that results in loss of the repressive H3K27me3 mark
and the acquisition of the activating H3K4me3 modification. This alteration
of chromatin structure in turn facilitates the activation of transcription from
the Ebf1 promoter region.
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associated with the Ebf1a
and Ebf1b promoters as well
as enhancer regions in wild-
type hematopoietic progeni-
tors and this in turn is corre-
lated with low levels of H2A
ubiquitination. Consistent
with the expectation that
MYSM1 is required to deubi-
quitinate H2A at the Ebf1
gene regulatory elements,
the amounts of ubH2A were
substantially increased at the
Ebf1a and Ebf1b promoters
inMysm1/ lineage negative
(Lin) progenitors. This mo-
lecular defect was associated
with a failure to properly
induce transcription of the
Ebf1 gene. As mentioned
above, histone ubiquitination
is accompanied by other
histone modifications that
affect the dynamic struc-
ture of chromatin. Therefore,
Jiang et al. analyzed addi-
tional histone modifications
at the Ebf1 promoters and/
or enhancer region that
were impacted by the loss
of MYSM1. The repressive
histone mark H3K27me3
was significantly elevated,
whereas the activating mark
H3K4me3 was decreased inMysm1/ Lin progenitors. Intriguingly,
histone modifications induced by
MYSM1 appeared to be also required for
the binding of the transcription factor
E2A to the Ebf1 regulatory elements.
These data strongly suggest that
MYSM1 deubiquitinates H2A at regula-
tory elements in the Ebf1 gene, and this
is associated with two key molecular
outcomes, the replacement of repressive
histone marks with their activating coun-
terparts and the facilitation of binding of
E2A, which is required for activation of
the Ebf1 gene (Figure 1).
These observations raise key issues
concerning the ordering of molecular
events that are required for the develop-
mental induction of the Ebf1 gene. How
is MYSM1, which lacks a DNA binding
domain and is not known to be associated
with a DNA binding subunit, targeted to
Ebf1 regulatory elements? Furthermore
how does it facilitate the binding of E2A?848 Immunity 35, December 23, 2011 ª2011The authors provide some intriguing clues
that suggest a parsimonious explanation.
MYSM1 was shown to interact with E2A
by coimmunoprecipitation and the two
factors could be detected cobound on
theEbf1 promoter and/or enhancer region
with sequential immunoprecipitation and
ChIP assays. These results implied a
concerted molecular mechanism in which
E2A is responsible for recruiting MYSM1
to the Ebf1 gene regulatory elements
and MYSM1 in turns enhances E2A
binding by inducing localized alterations
in nucleosome structure. Consistent with
this model, MYSM1 was also seen to
associate with BRM or Brahma-related
gene 1 (BRG-1), the ATPase subunits of
the SWI/SNF nucleosome-remodeling
complex, at the Ebf1 promoters.
The findings of Jiang et al. nicely
converge with recent work of Oguro
et al. (2010), which undertook genetic
analysis of the chromatin regulator Bmi1Elsevier Inc.in the context of hematopoi-
esis and B cell development.
Bmi1 interacts with Ring1B
and is associated with
components of Polycomb
group (PcG) complexes that
mediate H2A ubiquitination.
Loss of Bmi1 results in
enhanced expression of the
Ebf1 and Pax5 genes in mul-
tipotential hematopoietic pro-
genitors and an increased
potential to generate B line-
age cells at the expense of
the T cell fate. Intriguingly
Jiang et al. have shown that
loss of MYSM1 results in
increased binding of Bmi1 to
the Ebf1 promoter region.
Thus, it appears that Bmi1,
perhaps as a component of
a PcG complex, functions in
the establishment of a re-
pressed chromatin state at
the Ebf1 promoters and
enhancer region that is de-
pendent on ubH2A and
H3K27me3. This state is then
altered by the action of E2A-
associated MYSM1, resulting
in the developmental induc-
tionof theEbf1gene (Figure1).
Given that one of the down-
stream consequences of H2A
monoubiquitination is RNA
polymerase (pol) II pausing(Stock et al., 2007), it will be interesting
to determine whether the Ebf1 gene, in
its repressed state, is already poised for
developmental activation with a paused
polymerase complex. In this scenario,
binding of the E2A-MYSM1 complex
may additionally enable release of the
paused Pol II complex. Although the data
presented by Jiang et al. make a compel-
ling case for the Ebf1 gene as a major
biologically relevant target for the E2A-
MYSM1 complex during B cell fate speci-
fication, there are likely to be other impor-
tant targets for this complex. ChIPseq
analyses of E2A and MYSMI in wild-type
and Tcf3/ or Mysm1/ hematopoietic
progenitors can be used for elucidating
the nature of common targets as well as
those that are unique to each factor. It is
likely that MYSM1 can associate with
other transcription factors to target genes
for H2A deubiquitination. The proposed
genomic analyses can be complemented
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sequencing and characterization of
protein subunits of MYSM1 complexes
purified from B-lineage progenitors.
Nonetheless, the findings of Jiang et al.
highlight a major epigenetic switch that
needs to be activated by targeted H2A
deubiquitination of nucleosomes that
span the promoter and enhancer region
of theEbf1 gene to start off B cell develop-
ment. That is quite A-MYSM!
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In this issue of Immunity, Duprez et al. (2011) demonstrate that necroptosis, a form of regulated necrosis
that is mediated by the kinases RIPK1 and RIPK3, underlies the lethal effects of tumor necrosis factor
in vivo.The discovery that death receptors can—
at least in specific circumstances—initiate
either apoptotic or necrotic cell death
(Vercammen et al., 1998) has ignited an
intense wave of investigation. As a result,
nearly 15 years later, necrosis is no
longer considered as a merely accidental
cell death subroutine and the molecular
mechanisms that control regulated
necrosis have begun to emerge (Galluzzi
et al., 2012). One of the best-character-
ized signaling cascades that leads to
necrotic cell death is triggered by the liga-
tion of death receptors, mainly tumor
necrosis factor receptor 1 (TNFR1), in
conditions inwhich caspases, in particular
caspase-8, are inactivated (by pharmaco-
logical agents, the transfection of viral
proteins with caspase-inhibitory func-
tions, or genetic means) (Vandenabeeleet al., 2010). This peculiar form of regu-
lated necrosis, necroptosis, requires
the kinase activity of the TNFR1 interactor
receptor-interacting protein kinase 1
(RIPK1) as well as of its close homolog
RIPK3 and is executed by a bioenergetic
catastrophe featuring the overgeneration
of reactive oxygen species and increased
metabolic fluxes through glycolysis,
glycogenolysis, and glutaminolysis (Van-
denabeele et al., 2010). It has become
clear that necroptosis plays an important
role in multiple pathophysiological set-
tings, including ischemia-reperfusion
injury, cerulein-induced acute pancrea-
titis, viral infection, and retinal detach-
ment-induced photoreceptor cell death
(Vandenabeele et al., 2010). Moreover,
accumulating evidence indicates that pro-
apoptotic proteins including caspase-8and FADD are critical for embryonic and
postembryonic development as they toni-
cally inhibit regulated necrosis (Kaiser
et al., 2011; Zhang et al., 2011). In this
issue of Immunity, Duprez et al. (2011)
demonstrate that necroptosis constitutes
a prime etiological determinant for
both systemic inflammatory response
syndrome (SIRS) and hypoinflammatory
sepsis. In doing so, these authors not
only add two entries to the ever-growing
list of clinically relevant conditions that
may benefit from necroptosis-targeted
therapies, but also cast doubts on the
long-standing notion whereby the lethality
of SIRSwould directly result from a ‘‘cyto-
kine storm’’ associated with multiorgan
failure (Hotchkiss and Karl, 2003).
As a first step to elucidate the relative
contribution of apoptotic and necroticecember 23, 2011 ª2011 Elsevier Inc. 849
